Experimental approaches such as pharmacological inhibition of α-synuclein aggregation, targeted genetic manipulations, or in vitro ENS cultures could help delineate causative relationships and identify potential therapeutic targets for PD-related GI dysfunction. This evidence concerns the gene SNCA and Parkinson disease.